Two more RDTC QAAs have been published to the COVID-19 page of the RDTC website:

1. Q: [What resources are available to support prescribing for and care of respiratory patients with asthma or COPD during the COVID-19 pandemic?](https://rdtc.nhs.uk/sites/default/files/12-rdtc-gmmmg-covid-19-qaa-prescribing-for-asthma-and-copd-guidance-version-1.pdf)

A: There are numerous resources available to aid asthma and COPD prescribing during the COVID19 pandemic. These are being constantly revised and updated and this document will be regularly reviewed to pull these resources into one source. A link to BTS information around supply of inhalers is included.

1. Q: [**“Can monitoring intervals be extended for adults prescribed shared care drugs and other drugs that require monitoring during the COVID-19 pandemic?”**](https://rdtc.nhs.uk/sites/default/files/11-rdtc-gmmmg-covid-19-qaa-extended-monitoring-intervals-version-1.pdf)

A: Following publication of SPS guidance on the management of drugs that require monitoring during the COVID-19 pandemic, RDTC has developed practical guidance to aid prescribers. Currently included are DMARDs (azathioprine, leflunomide, mercaptopurine, methotrexate, sulfasalazine, ciclosporin and penicillamine when used for rheumatological conditions), warfarin, Lithium. This guidance has been produced in collaboration with the Greater Manchester Medicines Management Group and specialist clinical teams in Greater Manchester, RDTC has extrapolated the SPS recommendations on DMARDs to apply to other indications for which GMMMG shared care protocols apply. We are aware of other resources becoming available that contain advice regarding drug monitoring during the COVID-19 pandemic, as this is a rapidly changing area, resources will be evaluated and revised regularly. This document is being updated and expanded to include other medicines which require routine monitoring within primary care. Your comments to develop this resource are appreciated.